Health disparities among African-American and Hispanic drug injectors - HIV, AIDS, hepatitis B virus and hepatitis C virus: A review

AIDS

Volumn 19, Issue SUPPL. 3, 2005, Pages

  Estrada, Antonio L ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

African american; AIDS; Health disparities; Hepatitis B virus; Hepatitis C virus; Hispanic; HIV; Injection drug users

Indexed keywords

DIAMORPHINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICAN AMERICAN; BLOOD; CAUCASIAN; CHRONIC DISEASE; COMMUNITY; ETHNIC DIFFERENCE; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEROIN DEPENDENCE; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; INJECTION; MEDICAL DOCUMENTATION; MORBIDITY; MORTALITY; NONHUMAN; OUTCOMES RESEARCH; PATIENT CARE; PATIENT COUNSELING; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SEXUALITY; VIRUS PATHOGENESIS;

EID: 27944480405     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000192070.95819.7c     Document Type: Review

References (39)

1. Smedley GD, Stith AY, Nelson AR, editors. Unequal treatment: confronting racial and ethnic disparities in health care. Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, Board on Health Sciences Policy, Institute of Medicine. Washington, DC: National Academy of Sciences Press; 2003.
2. House JS, Williams D. Understanding and reducing socioeconomic and racial/ethnic disparities in health. In: Smedley BD, Syme SL, editors. Promoting health: intervention strategies from social and behavioral research. Washington, DC: National Academy Press; 2000.
3. Buka SL. Disparities in health status and substance use: ethnicity and socioeconomic factors. Public Health Rep 2002; 117 (Suppl.):S118-S125.
4. National Center for Health Statistics. Health, United States, 2003. Hyattsville, MD: National Center for Health Statistics; 2003.
5. McQuillan GM, Coleman P, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89:14-18.
6. McQuillan GM, Alter MJ, Moyer LA, Lambert SB, Margolis HS. A population based serologic study of hepatitis C virus infection in the United States. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, editors. Viral hepatitis and liver disease. Turin: Edizioni Minerva Medica; 1997. pp. 267-270.
7. Estrada AL. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users. Public Health Rep 2002; 117 (Suppl. 1):S126-S134.
8. Monga HK, Rodriquez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33:240-247.
9. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450-456.
10. Zeldis J, Jain S, Kuramoto I, Richards C, Sazama K, Samuels S, et al. Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med 1992; 156:30-35.
11. Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AD, Nelson KE. Seroepidemiology of hepatitis B virus in a population of injecting drug users. Am J Epidemiol 1995; 142:331-341.
12. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (Suppl .1):S6-S10.
13. Levine OS, Vlahov D, Nelson K. Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors, and viral interactions. Epidemiol Rev 1994; 16:418-436.
14. Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis 2002; 185:713-719.
15. Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health 2000; 77:331-345.
16. Ward J, Mattick RP, Hall W. The effectiveness of methadone maintenance treatment: HIV and infectious hepatitis. In: Ward J, Mattick RP, et al., editors. Methadone maintenance treatment and other opioid replacement therapies. Amsterdam, Netherlands: Harwood Academic Publishers; 1998. pp. 59-73.
17. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2003. Vol. 15. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2004.
18. Diaz T, Des Jarlais DC, Vlahov D, Perlis TE, Edwards V, Friedman SR, et al. Factors associated with prevalent hepatitis C: Differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Pub Health 2001; 91:23-30.
19. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE. Correlates of hepatitis C virus among injection drug users. Medicine 1995; 74:212-220.
20. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655-661.
21. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35:3274-3277.
22. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Pub Health 2001; 91:42-46.
23. Johnston LD, O'Malley PM, Bachman JG. Monitoring the future national survey results on drug use, 1975-2002, Vol. II: college students and adults aged 19-40. NIH publication no. 03-5376. Bethesda, MD: National Institute on Drug Abuse; 2003.
24. National Institute on Drug Abuse. Drug use among racial/ethnic minorities. NIH publication no. 03-3888. Bethesda, MD: National Institute on Drug Abuse; 2003.
25. Estrada AL. Drug use and HIV risks among African American, Mexican American, and Puerto Rican drug injectors. J Psychoactive Drugs 1998; 30:247-253.
26. Chamot E, de Saussure P, Hirschel B, Deglon JJ, Perin LH. Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone maintenance programme. [Letter]. AIDS 1992; 6:430-431.
27. Lopez-Zetina J, Kerndt P, Ford W, Woerhle T, Weber M. Prevalence of HIV and hepatitis B and self-reported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994-1996. Addiction 2001; 96:589-595.
28. Markides KS, Coreil J. The health of Hispanics in the south-western United States: an epidemiological paradox. Public Health Rep 1986; 101:253-265.
29. De la Torre A, Estrada AL. Mexican Americans and Health. Tucson: The University of Arizona Press; 2001.
30. Goldstein MF, Friedman SR, Neaigus A, Jose B, Iidefonso G, Curtis R. Self-reports of HIV risk behavior by injecting drug users: are they reliable? Addiction 1995; 90:1097-1104.
31. Fisher DG, Kuhrthunstiger TI, Orr SM, Davis DC. Hepatitis B validity of drug users' self-report. Psychol Addict Behav 1999; 13:33-38.
32. National Institutes of Health. Consensus development statement: Management of hepatitis C. NIH Consensus Development Conference on the management of Hepatitis C. 24-26 March 1997. Bethesda, MD: National Institutes of Health; 1997.
33. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149:203-213.
34. Hagan H, Des Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Pub Health 1995; 85:1490-1491.
35. Mansson AS, Moestrup T, Nordenfelt E, Widell A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis 2000; 32:253-258.
36. Strathdee SA, Celentano DD, Shah N, Lyles C, Stambolis VA, Macalino G, et al. Needle-exchange attendance and health care utilization promote entry into detoxification. J Urban Hlth 1999; 76:448-460.
37. Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treatment 2000; 19:247-252.
38. Gunn RA, Murray PJ, Ackers ML, Hardison WG, Margolis HS. Screening for chronic hepatitis B and C infections in an urban sexually transmitted disease clinic: rationale for integrating services. Sex Transm Dis 2001; 28:166-170.
39. Centers for Disease Control and Prevention (CDC). Prevention and control of infections with hepatitis viruses in correctional settings. MMWR 2003; 52(RR01):1-33.